· Published by Health Canada · Official notice
This is duplicated text of a letter from EMD Serono Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
Dear Health Care Professional,
This Communication is to inform you that EMD Serono Canada Inc. has formally withdrawn the market authorization of RAPTIVA in Canada as of June 8, 2009.
EMD Serono Canada Inc., the company that markets RAPTIVA in Canada has decided, in consultation, with Health Canada, to terminate marketing of Raptiva (efalizumab) in Canada, due to safety concerns.
RAPTIVA is an immunomodulating, humanized monoclonal antibody which was authorized in Canada in 2005 for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any occurrence of serious and/or unexpected adverse reactions in patients who received RAPTIVA should be reported to EMD Serono Canada Inc., or Health Canada at the following addresses:
EMD Serono Canada Inc.,
2695 North Sheridan Way, Suite 200
Mississauga ON L5K 2N6
Telephone: 1-888-737-6668 ext. 5160
Fax: 905-919-0292
E-mail: drugsafetycanada@merckserono.net
Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 1-866-234-2345
Fax: 1-866-678-6789
CanadaVigilance@hc-sc.gc.ca
The Adverse Reaction Reporting Form and the Adverse Reaction Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions regarding the withdrawal of RAPTIVA, please call the EMD Serono Medical Information/Drug Safety Department at 1-888-737-6668 x 5160.
original signed by
Peter Grosser, Ph.D.
Director, Regulatory Affairs, Drug Safety & Medical Information
EMD Serono Canada Inc.